Nasal Polyposis Treatment Market By Treatment Type (Corticosteroids, Biologic Therapies, Surgery, Antibiotics & Adjunctive Agents); By Route of Administration (Intranasal, Parenteral, Oral); By Disease Type (CRSwNP, AERD, Idiopathic Nasal Polyposis); By End User (Hospitals & ENT Clinics, Ambulatory Surgical Centers, Retail & Specialty Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Nasal Polyposis Treatment Market is projected to grow steadily at an CAGR of 6.4% , valued at around USD 4.8 billion in 2024 and expected to reach nearly USD 7.3 billion by 2030 , according to Strategic Market Research.

 

Nasal polyposis — often linked to chronic rhinosinusitis — represents one of the most persistent inflammatory airway conditions, creating a growing economic and clinical burden worldwide.

 

At its core, nasal polyposis is a chronic inflammatory disorder of the mucosa, marked by benign but obstructive growths in the nasal cavity and sinuses. It primarily affects adults and is closely tied to conditions like asthma, allergic rhinitis, and aspirin-exacerbated respiratory disease (AERD). Over the past decade, the approach to treatment has shifted dramatically — moving away from repetitive surgery and corticosteroid cycles toward precision biologic therapies that target the underlying inflammatory pathways.

 

So, what’s driving this evolution? First, awareness is increasing. With improved diagnostic imaging and ENT consultation access, more patients are being accurately diagnosed earlier. Second, biologics such as anti-IL-4, anti-IL-5, and anti- IgE monoclonal antibodies are transforming treatment expectations. Patients once resigned to frequent endoscopic sinus surgeries are now responding to targeted drug therapies that modify disease progression rather than just symptoms.

 

From a policy standpoint, reimbursement frameworks for biologic treatments are expanding, especially across the U.S., Western Europe, and Japan. Governments and payers are beginning to recognize nasal polyposis as a chronic inflammatory disease that significantly impacts quality of life — not just a localized ENT issue. In developing regions, however, affordability gaps remain, leading to heavy reliance on corticosteroid sprays and oral treatments.

 

Clinically, the narrative is changing fast. ENT specialists and immunologists now collaborate more closely to manage complex, comorbid cases. Digital nasal endoscopy tools and point-of-care diagnostic platforms are making evaluations more precise. Also, tele-ENT consults are emerging as a practical bridge in regions with limited specialty access.

 

The stakeholder ecosystem here is diverse. Pharmaceutical companies are leading innovation with biologic therapies and intranasal corticosteroid reformulations. Medical device firms are improving surgical instrumentation and sinus delivery systems. Hospitals and outpatient ENT centers are enhancing care pathways for chronic sinusitis patients. And investors are taking note — the shift toward biologics and long-term disease management models makes this a recurring revenue market with low patient churn.

 

Market Segmentation And Forecast Scope

The nasal polyposis treatment market can be divided along several clear lines — from the type of therapy used to the route of administration and treatment setting. Each segment reflects how healthcare systems and physicians balance efficacy, cost, and patient adherence in managing this chronic and often recurrent disease.

By Treatment Type
Therapeutic options for nasal polyposis have evolved rapidly. Corticosteroids remain the first line, but biologics are rewriting the playbook.

• Corticosteroids: Still the backbone of therapy, both intranasal and oral forms are used for inflammation control and symptom relief. Despite widespread use, long-term dependency and recurrence risks are prompting a gradual shift toward alternatives.

• Biologic Therapies: The fastest-growing category, biologics target interleukins and IgE pathways to control chronic inflammation at its source. Drugs like dupilumab and omalizumab are gaining traction, especially among patients unresponsive to steroids or surgery.

• Surgery (Endoscopic Sinus Surgery): Used when medical therapy fails, though recurrence rates remain significant. Advancements in endoscopic tools have reduced recovery times, but biologics are reducing the need for repeat interventions.

• Antibiotics and Adjunctive Agents: Used primarily for secondary infections, they remain part of the supportive care ecosystem but play a smaller role in chronic disease management.

In 2024, biologics are estimated to account for roughly 28% of the market but are expected to surpass 40% by 2030 as clinical guidelines shift and affordability improves across key markets.

 

By Route of Administration
Therapeutic delivery methods have become an important differentiator in treatment adherence and patient comfort.

• Intranasal: The most common route, covering sprays and irrigations. Modern formulations feature better mucosal absorption and minimal systemic side effects.

• Parenteral (Injectable): The preferred route for biologic therapies, with increasing adoption in hospital and specialty clinic settings.

• Oral: Used mainly for short corticosteroid courses, though their systemic effects limit long-term usage.

Intranasal delivery continues to dominate volume, but parenteral biologics are driving revenue growth and clinical outcomes alike.

 

By Disease Type

• Chronic Rhinosinusitis with Nasal Polyps ( CRSwNP ): The primary market driver, representing the majority of diagnosed cases.

• Aspirin-Exacerbated Respiratory Disease (AERD): A smaller yet critical segment where biologics show particularly high efficacy.

• Idiopathic Nasal Polyposis: Represents less than 10% of cases but remains clinically challenging due to poor response to conventional treatments.

 

By End User

Treatment dynamics differ depending on care setting:

• Hospitals and ENT Clinics: Handle complex cases, biologic therapy initiation, and surgical interventions.

• Ambulatory Surgical Centers (ASCs): Manage minimally invasive sinus procedures and follow-ups.

• Retail and Specialty Pharmacies: Serve as key distribution channels for biologics and maintenance therapies, especially in the U.S. and Europe.

Hospitals currently lead in treatment volume, while specialty pharmacies are expanding their role in biologic dispensing and patient adherence programs.

 

By Region

• North America: Dominates the global market due to early adoption of biologics, structured reimbursement, and a high prevalence of chronic sinusitis.

• Europe: Follows closely with strong national health programs and standardized ENT referral systems.

• Asia Pacific: Expected to grow the fastest, fueled by urbanization, air pollution exposure, and improving healthcare access in China, Japan, and India.

• Latin America, Middle East & Africa: Smaller but steadily expanding markets, supported by government ENT awareness campaigns and growing biologic access through public health programs.

 

Market Trends And Innovation Landscape

The nasal polyposis treatment market is going through a transformation driven by biologics, device innovation, and precision diagnostics. What used to be a surgical and steroid-heavy field is rapidly becoming a data-driven, immunology-led therapeutic space. Between 2024 and 2030, most of the innovation revolves around biologic pipeline expansion, improved drug delivery systems, and digital support platforms for chronic care management.

Biologic Therapies Redefine the Treatment Standard
The biggest change is happening at the molecular level. Biologics that target Type 2 inflammation are altering how clinicians approach long-term management. Drugs like dupilumab (anti–IL-4/IL-13) have set a new bar for symptom control and recurrence prevention. Similar candidates — such as tezepelumab (anti–TSLP) and mepolizumab (anti–IL-5) — are expanding treatment choice beyond corticosteroids and surgery. Clinical trials are also exploring combinations of biologics and topical agents to enhance mucosal healing and reduce dosing frequency.

What’s interesting is that payers are beginning to support biologic use beyond severe cases, especially in the U.S. and parts of Europe. As one ENT specialist put it, “We’re finally treating the root cause, not just clearing tissue and waiting for it to grow back.”

 

Smart Drug Delivery and Novel Formulations
Delivery technology is catching up fast. Intranasal sprays are evolving into high-precision devices with improved particle dispersion and target-site deposition. Some companies are working on bioadhesive nasal gels that increase residence time in the sinus cavity. Sustained-release corticosteroid implants — once niche — are becoming standard for post-surgical maintenance. These implants allow for localized, slow-release dosing over months, minimizing systemic side effects.

Another emerging area is sinus-targeted biologic delivery. Biologic microdosing through endoscopic-guided injection could soon become a bridge between oral steroids and full biologic therapy — especially for patients with unilateral or localized polyps.

 

Digital ENT and Remote Monitoring
Tele-ENT consultations and digital follow-up platforms are gaining traction. Patients with chronic sinusitis and polyposis often require frequent monitoring, which burdens clinics. New digital tools now allow patients to record symptom changes, medication adherence, and nasal airflow metrics from home. These data feed directly into ENT dashboards for proactive treatment adjustments.

Digital engagement isn’t just convenience; it’s disease control. Early adopters in Japan and Germany are integrating AI-based sinus imaging analysis into diagnostic workflows, shortening evaluation times and improving surgical decision-making.

 

AI and Predictive Diagnostics in Nasal Disorders
AI is making its way into diagnostic ENT practice. Machine learning algorithms are being trained on CT and MRI sinus scans to classify polyp severity and predict recurrence probability post-surgery. These predictive models are expected to help physicians decide whether a patient will benefit more from surgery, biologic therapy, or combined care.

AI is also being applied to drug response modeling . Early research from Europe suggests that genomic data tied to inflammatory biomarkers could soon personalize biologic selection for individual patients. That could mean moving from broad prescription patterns to tailored immunologic profiling within this decade.

 

Sustainability and Green Manufacturing
Environmental sustainability is emerging as a subtle but important theme. Nasal sprays, once dominated by single-use plastics and propellants, are being reformulated into eco-friendly packaging and refillable units. Biologic manufacturers are also optimizing production pipelines for lower carbon footprints. Though not yet a purchasing driver, these changes will matter more as healthcare systems set sustainability mandates for pharmaceuticals.

 

Strategic Collaborations and Mergers
In the past two years, strategic alliances between pharmaceutical and device firms have surged. Drug–device hybrids — such as combination therapies that pair corticosteroid sprays with biologic maintenance — are entering clinical evaluation. ENT equipment manufacturers are also partnering with pharma companies to integrate drug-delivery-compatible endoscopes.

 

Competitive Intelligence And Benchmarking

The nasal polyposis treatment market is now shaped by a mix of global pharmaceutical giants and emerging biotech innovators competing on biologic efficacy, access strategy, and long-term treatment outcomes. Unlike traditional drug markets, differentiation here lies not in formulation alone but in how well each company integrates immunology, delivery, and patient experience.

GlaxoSmithKline (GSK)
GSK has been an early leader in Type 2 inflammation therapies, primarily through its biologic Nucala (mepolizumab). Originally developed for severe eosinophilic asthma, it has shown significant benefit in chronic rhinosinusitis with nasal polyps ( CRSwNP ). The company’s competitive edge comes from broad experience with respiratory inflammation and its ability to reposition biologics across adjacent diseases. GSK’s expansion strategy includes market education for ENT specialists and payers, aiming to normalize biologic use earlier in disease progression.

 

Sanofi and Regeneron Pharmaceuticals
This partnership dominates the biologic segment through Dupixent (dupilumab), currently the benchmark biologic for CRSwNP . Sanofi and Regeneron’s strength lies in evidence generation — their global trial network continues to expand the label into moderate cases and pediatric applications. They also focus heavily on physician awareness programs and patient-support frameworks to reduce drop-off rates in chronic therapy. Their dual emphasis on data transparency and real-world outcomes makes them the most trusted pair in biologic innovation for nasal polyposis.

 

AstraZeneca
AstraZeneca is developing next-generation biologics targeting upstream cytokines like TSLP through Tezspire ( tezepelumab ). Early studies show promise in controlling inflammation earlier in the immune cascade, potentially benefiting patients who fail anti–IL-4 or anti–IL-5 treatment. The company is also investing in companion diagnostic tools to better identify biologic responders — a move that may give them a predictive edge in treatment personalization.

 

Novartis
Novartis has a strong respiratory portfolio anchored in its experience with Xolair (omalizumab), an anti- IgE biologic approved for nasal polyposis in many regions. Its commercialization strategy hinges on physician training and payer negotiation, especially in markets like the U.S. and Japan. The company’s broad immunology pipeline and experience in chronic inflammatory diseases position it well for long-term competition, though its biologic costs remain a challenge in middle-income markets.

 

Bayer AG
Bayer’s approach focuses on combination therapy development and post-surgical maintenance. The company has advanced corticosteroid-eluting sinus implants that release drugs locally to prevent recurrence after endoscopic surgery. These devices bridge pharmacologic and mechanical solutions, making Bayer a notable player in procedural integration rather than pure drug development.

 

Intersect ENT (acquired by Medtronic)
Intersect ENT, now under Medtronic, has redefined localized delivery with its Propel and Sinuva bioresorbable implants. These innovations are widely used post-surgery to maintain sinus patency and provide sustained corticosteroid release. Their products complement biologic therapy rather than compete with it, often forming part of a combination management plan. This integration of drug-device delivery remains a differentiator for Medtronic within ENT therapeutics.

 

Emerging Biotech Players
Several smaller firms are gaining momentum with novel drug delivery technologies and next-generation anti-inflammatory compounds. Companies like Lyra Therapeutics and OptiNose are developing targeted nasal delivery systems designed for deep sinus deposition — a key unmet need in current treatment protocols. These firms are attractive acquisition targets for large pharmaceutical companies seeking to expand their ENT portfolios.

 

Competitive Landscape Snapshot
The market’s structure reflects a balance between innovation depth and commercial reach. Sanofi–Regeneron and GSK lead biologic adoption, while Medtronic and Bayer dominate the post-surgical device segment. AstraZeneca and Novartis bridge both therapeutic and preventive domains through biologics with expanding indications. Emerging firms, meanwhile, provide technological differentiation through delivery precision and cost-effective access models.

In essence, competition in this market isn’t defined by product count — it’s defined by disease control continuity. The players that can provide a seamless transition from acute management to chronic maintenance will lead the next phase of this industry. As biologics mature and delivery tech advances, partnerships between drug and device firms will increasingly define success.

 

Regional Landscape And Adoption Outlook

The nasal polyposis treatment market shows highly uneven adoption patterns worldwide, shaped by healthcare access, reimbursement systems, awareness levels, and infrastructure maturity. While North America and Western Europe dominate biologic usage, Asia-Pacific and emerging regions are rapidly scaling up through hospital expansion and rising ENT specialization. The real challenge lies in bridging affordability and clinical expertise across lower-income regions — an issue that defines the market’s next growth wave.

North America
North America leads the global nasal polyposis treatment landscape, largely due to high disease awareness, advanced ENT infrastructure, and favorable reimbursement coverage for biologics. The U.S. remains the largest single market, with biologics like dupilumab and mepolizumab integrated into clinical practice for chronic rhinosinusitis with nasal polyps. Insurers have gradually widened coverage criteria, making long-term biologic therapy more accessible for severe cases.

Academic centers such as the Mayo Clinic and Cleveland Clinic are driving early adoption of predictive diagnostics and biologic therapy sequencing, linking sinus disease management with broader asthma and allergy programs. Canada mirrors similar adoption patterns but faces regional disparities in access due to provincial formulary variations. The region’s future growth will hinge on earlier biologic initiation and tele-ENT integration in suburban and rural areas.

 

Europe
Europe’s adoption trends reflect its mature but cautious healthcare environment. Western European countries — particularly Germany, the UK, France, and the Netherlands — have incorporated biologics into standard ENT guidelines for recurrent nasal polyposis. National health systems have been relatively quick to fund biologic treatments once cost-effectiveness data were established.

The European Rhinologic Society and other academic bodies have supported awareness campaigns, improving early diagnosis rates. Moreover, combination therapy models — biologic plus topical corticosteroid — are gaining traction under value-based care programs. Eastern Europe, however, continues to lag behind due to limited reimbursement for advanced therapies and uneven ENT specialist distribution.

The region also shows strong activity in localized device innovation. Companies in Germany and Switzerland are pushing post-surgical sinus implants and biodegradable corticosteroid matrices — technologies that complement the medical management ecosystem. Europe’s balance of innovation and policy discipline makes it a predictable but highly stable growth environment.

 

Asia Pacific
Asia Pacific is the most dynamic region, showing the fastest growth from a small base. Rising pollution levels, urban allergies, and growing ENT awareness are expanding patient pools in China, Japan, South Korea, and India. Japan has already approved several biologics for nasal polyposis, supported by strong clinician networks and government-funded clinical trials.

China is still early in adoption, but local pharmaceutical firms are entering the biologics space through licensing deals with Western developers. India’s focus remains on affordable corticosteroid-based management, though leading hospitals in Delhi, Mumbai, and Bangalore are starting biologic therapy for high-severity patients. The region’s potential is enormous — population scale and growing private healthcare infrastructure could make Asia Pacific the second-largest market by 2030.

Another defining factor is telemedicine. South Korea and Singapore are integrating ENT teleconsults and digital nasal monitoring apps, reducing patient loss between diagnosis and treatment initiation. This hybrid digital-biologic model may set the tone for broader adoption across developing Asian nations over the next five years.

 

Latin America, Middle East, and Africa (LAMEA)
In Latin America, Brazil and Mexico dominate adoption due to established ENT programs and public–private hospital collaboration. Access to biologics remains limited but is improving as global pharma firms enter local reimbursement negotiations. Awareness campaigns focusing on chronic rhinosinusitis have increased diagnosis rates, especially in urban areas.

The Middle East, particularly Saudi Arabia and the UAE, is investing heavily in advanced ENT facilities and importing biologic treatments through government-backed health initiatives. The region’s private healthcare sector is also beginning to adopt biologics for patients previously dependent on repeated surgical interventions.

Africa remains the most underpenetrated market. Nasal polyposis is often underdiagnosed, and treatment depends on corticosteroids and antibiotics. However, NGO programs and telehealth projects are slowly introducing awareness and primary ENT care, particularly in South Africa and Kenya.

 

Regional Outlook Summary

• North America and Western Europe will continue to dominate biologic therapy adoption due to robust payer systems and clinician familiarity.

• Asia Pacific will register the fastest CAGR through 2030, driven by patient volume and increasing biologic localization.

• LAMEA offers long-term potential but requires substantial investment in awareness, infrastructure, and affordability frameworks.

 

End-User Dynamics And Use Case

The nasal polyposis treatment market revolves around a diverse mix of end users — hospitals, ENT specialty clinics, ambulatory surgical centers , and retail pharmacies — each shaping access and adherence in different ways. The disease’s chronic nature means that long-term patient engagement and multidisciplinary coordination are central to successful outcomes. End-user dynamics are, therefore, evolving from episodic surgical care toward integrated, biologic-led disease management models.

Hospitals and ENT Specialty Clinics
Hospitals, especially tertiary and teaching institutions, dominate the management of moderate to severe nasal polyposis cases. They handle the bulk of biologic initiation, advanced diagnostics, and surgical interventions. Many have developed multidisciplinary care pathways involving ENT surgeons, pulmonologists, allergists, and immunologists to manage overlapping respiratory conditions like asthma or allergic rhinitis.

These centers are also where biologics are first introduced to patients. Administration typically starts under clinical supervision before transitioning to home-based maintenance dosing. Hospitals further serve as referral hubs for endoscopic sinus surgery, with follow-up care transitioning to outpatient ENT clinics. Their ability to combine diagnosis, biologic initiation, and post-surgical monitoring makes them the cornerstone of care delivery in high-prevalence markets.

 

Ambulatory Surgical Centers (ASCs)
ASCs play an increasingly important role, especially in developed markets where minimally invasive procedures are becoming the standard. Endoscopic sinus surgery, polyp removal, and corticosteroid implant placement are commonly performed in these settings. The advantage lies in faster turnaround, lower costs, and reduced hospital burden. Many ASCs are now equipped with digital imaging systems and AI-assisted endoscopes for improved surgical precision.

That said, ASCs are not designed for biologic administration or complex comorbidity management, so they remain procedure-focused. However, collaborations between ASCs and hospital-based ENT units are emerging, creating a shared ecosystem where surgery and long-term medical management are better aligned.

 

Retail and Specialty Pharmacies
Pharmacies — particularly specialty ones — are gaining significance in biologic distribution and patient adherence support. In the U.S. and parts of Europe, biologic drugs like dupilumab are increasingly dispensed through pharmacy channels under home-administration programs. Pharmacists trained in biologic therapy assist patients with injection technique, storage, and refill reminders.

This shift is reducing hospital load and improving patient convenience. In markets with advanced digital infrastructure, pharmacy networks are beginning to integrate directly with hospital electronic records, creating near-seamless monitoring loops between prescribers and patients.

 

Primary Care Clinics
While not major prescribers, primary care physicians play a critical role in referral generation. Early diagnosis of nasal polyposis remains suboptimal, as symptoms often overlap with chronic sinusitis or allergies. As awareness improves, general practitioners are being trained to identify refractory cases earlier and refer them for specialized evaluation, helping expand the treated population base.

 

Use Case Example
A private ENT clinic in Germany partnered with a regional hospital network to pilot a combined biologic–digital monitoring model for patients with chronic rhinosinusitis and nasal polyps. Patients began dupilumab therapy at the hospital, then transitioned to home-based administration supported by a mobile app that tracked symptom scores, nasal airflow, and medication adherence.

Within six months, the program achieved notable results: a 32% reduction in unscheduled ENT visits, a 45% drop in repeat corticosteroid use, and measurable improvement in sleep quality and patient-reported nasal congestion scores. Clinicians could view real-time adherence dashboards, allowing early intervention when symptom scores rose. This integration between hospital initiation and digital pharmacy monitoring demonstrates how end-user collaboration can turn chronic nasal disease into a managed condition rather than a recurring surgical problem.

 

End-User Outlook
Hospitals and ENT specialty centers will continue to drive biologic adoption and guideline implementation, while pharmacies and ASCs will expand the accessibility and efficiency of treatment delivery. In emerging markets, however, public hospitals remain constrained by cost and infrastructure limitations, which keeps corticosteroids dominant. Still, as awareness, digital tracking, and biologic affordability improve, the ecosystem is gradually shifting from episodic care to continuous management.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

• In 2024 , Sanofi and Regeneron Pharmaceuticals announced new clinical data extending Dupixent’s indication to patients with moderate nasal polyposis, demonstrating over 55% reduction in polyp size and sustained symptom relief. The expanded label is expected to boost mid-severity patient adoption in the U.S. and Europe.

• AstraZeneca completed late-stage trials for Tezepelumab , an anti-TSLP biologic showing promising results in patients who are non-responsive to IL-4 and IL-5 inhibitors. The therapy could redefine the biologic treatment sequence by 2026.

• GSK received regulatory approval in multiple European markets for mepolizumab in chronic rhinosinusitis with nasal polyps, strengthening its respiratory and ENT portfolio integration.

• Medtronic (Intersect ENT) launched an upgraded version of its Sinuva steroid-eluting implant with optimized drug release kinetics, designed to maintain sinus patency longer post-surgery and reduce polyp recurrence.

• In 2023 , Novartis expanded its Xolair (omalizumab) approval for nasal polyposis in Japan and Canada, positioning it as a key anti- IgE therapy across Asia-Pacific.

• Several digital health startups, including Lyra Therapeutics , piloted smart nasal delivery systems that combine sustained corticosteroid release with in-app adherence tracking, signaling the next phase of personalized sinus care.

 

Opportunities

• Biologic Expansion in Emerging Markets: Growing hospital infrastructure in Asia-Pacific and Latin America opens the door for biologic therapies as governments and insurers begin partial reimbursement programs.

• Precision Immunology: Genomic profiling and biomarker-based patient selection will improve biologic response rates, enhancing both efficacy and cost-effectiveness.

• Combination Therapy Models: Pairing biologics with localized drug delivery (implants, sprays) creates a synergistic approach, reducing recurrence and improving adherence.

• Digital Monitoring Integration: ENT teleconsultations and AI-based sinus imaging analysis platforms will help physicians manage chronic cases remotely and adjust biologic dosing schedules dynamically.

• Shift from Surgery to Maintenance Therapy: The gradual decline in repeat endoscopic sinus surgeries signals market maturity and rising long-term revenue potential for maintenance-based biologic regimens.

 

Restraints

• High Biologic Cost: The average annual cost of biologic treatment still exceeds affordability thresholds for most patients in low- and middle-income countries, slowing equitable adoption.

• Limited Specialist Availability: The shortage of ENT and allergy specialists in developing nations constrains early diagnosis and biologic administration capacity.

• Reimbursement Gaps: Inconsistent insurance coverage for biologic therapies, particularly in Asia-Pacific and Eastern Europe, limits patient access despite clinical efficacy.

• Adherence Challenges: Chronic administration fatigue and delayed follow-ups can lead to discontinuation, undermining long-term disease control outcomes.
   

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 4.8 Billion
Revenue Forecast in 2030	USD 7.3 Billion
Overall Growth Rate	CAGR of 6.4% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Treatment Type, Route of Administration, Disease Type, End User, Geography
By Treatment Type	Corticosteroids, Biologic Therapies, Surgery (Endoscopic Sinus Surgery), Antibiotics & Adjunctive Agents
By Route of Administration	Intranasal, Parenteral (Injectable), Oral
By Disease Type	Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Aspirin-Exacerbated Respiratory Disease (AERD), Idiopathic Nasal Polyposis
By End User	Hospitals & ENT Clinics, Ambulatory Surgical Centers (ASCs), Retail & Specialty Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, UK, France, China, Japan, India, Brazil, Saudi Arabia, South Africa
Market Drivers	- Growing shift from surgery to biologic maintenance therapies - Rising prevalence of chronic rhinosinusitis and Type 2 inflammation disorders - Increasing adoption of digital and remote ENT monitoring platforms
Customization Option	Available upon request